Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654

Showing 26-50 of 654 citing articles:

Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations
Natalie McCormick, Chio Yokose, Jie Wei, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 8, pp. 1067-1080
Closed Access | Times Cited: 29
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout
Jordana Dinorá de Lima, André Guilherme Portela de Paula, Bruna Sadae Yuasa, et al.
Immunological Investigations (2023) Vol. 52, Iss. 3, pp. 364-397
Closed Access | Times Cited: 26
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
Lisa K. Stamp, Anne Horne, Borislav Mihov, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1626-1634
Closed Access | Times Cited: 25
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Chio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 216-231
Closed Access | Times Cited: 14
Controversies and practical management of patients with gout and chronic kidney disease
Richard J. Johnson, Brian F. Mandell, Naomi Schlesinger, et al.
Kidney International (2024) Vol. 106, Iss. 4, pp. 573-582
Closed Access | Times Cited: 13
Large-scale cross-ancestry genome-wide meta-analysis of serum urate
Chamlee Cho, Beomsu Kim, Dan Say Kim, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Well-defined alginate oligosaccharides ameliorate joint pain and inflammation in a mouse model of gouty arthritis
Chengyu Yin, Qianqian Lyu, Zishan Dong, et al.
Theranostics (2024) Vol. 14, Iss. 8, pp. 3082-3103
Open Access | Times Cited: 11
Asymptomatic Hyperuricemia and the Kidney: Lessons from the URRAH Study
Cecilia Barnini, Elisa Russo, Giovanna Leoncini, et al.
Metabolites (2025) Vol. 15, Iss. 1, pp. 11-11
Open Access | Times Cited: 1
Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression
Hamlet Ghukasyan, Denilsa Navalha, Ignacio Pérez Romero, et al.
Endocrinología Diabetes y Nutrición (English ed ) (2025) Vol. 72, Iss. 1, pp. 26-36
Closed Access | Times Cited: 1
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline
Magdalena Madero, Adeera Levin, Sofia B. Ahmed, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Dotinurad treatment for patients with hyperuricemia complicating chronic kidney disease
Katsuyuki Tanabe, Tomokazu Nunoue, Naoki Itabashi, et al.
Kidney International Reports (2025)
Open Access | Times Cited: 1
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson, John Tesser, Ralph Bennett, et al.
The Journal of Rheumatology (2020) Vol. 48, Iss. 5, pp. 767-774
Open Access | Times Cited: 53
Systemic Urate Deposition: An Unrecognized Complication of Gout?
Puja Khanna, Richard J. Johnson, Bradley Marder, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3204-3204
Open Access | Times Cited: 52
A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine
Chiraphat Kloypan, Napatrupron Koomdee, Patompong Satapornpong, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 11, pp. 1077-1077
Open Access | Times Cited: 50
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
Mareev VIu, Yа. A. Orlova, A. G. Plisyk, et al.
Kardiologiia (2021) Vol. 61, Iss. 2, pp. 15-27
Open Access | Times Cited: 44
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
Puja Khanna, Dinesh Khanna, Gary Cutter, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 8, pp. 1523-1532
Closed Access | Times Cited: 43
Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13
Open Access | Times Cited: 36
The Anti-Inflammatory and Uric Acid Lowering Effects of Si-Miao-San on Gout
Ling Cao, Tianyi Zhao, Yu Xue, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 31
Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease
Jie Wei, Hyon K. Choi, Tuhina Neogi, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 4, pp. 461-470
Open Access | Times Cited: 30
Shared decision making in rheumatology: A scoping review
Tessalyn Morrison, Erin Foster, Jacob Dougherty, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 56, pp. 152041-152041
Closed Access | Times Cited: 29
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase
Mai Sekine, Ken Okamoto, E.F. Pai, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 9, pp. 105189-105189
Open Access | Times Cited: 22
Immune and inflammatory mechanisms and therapeutic targets of gout: An update
Wenji Liu, Jie Peng, Yixin Wu, et al.
International Immunopharmacology (2023) Vol. 121, pp. 110466-110466
Closed Access | Times Cited: 21
Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
Naomi Schlesinger, Michael H. Pillinger, Lee S. Simon, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 21
Cumulative Serum Uric Acid Exposure and Its Time Course With the Risk of Incident Stroke
Xue Tian, Shuohua Chen, Qin Xu, et al.
Stroke (2023) Vol. 54, Iss. 8, pp. 2077-2086
Open Access | Times Cited: 20
Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis
Yuxin Luo, Qirong Song, Jiaxiao Li, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 8

Scroll to top